• Approx 15 years’ experience in economic consultancy.• Excellent quantitative and qualitative analytical skills including experience in cost-effectiveness, cost-minimisation, cost-utility and cost-benefit analysis. • Substantial experience in the development and leadership of the development of economic models and modelling for Health Technology Assessment submissions in a wide variety of countries, including England, Wales, Scotland, Ireland, Sweden, Norway, Czech Republic, Hungary, Spain, Italy, Belgium, Greece, Switzerland, France, Germany, Brazil, Mexico, South Korea and Israel.• Track record of representing clients at HTA committee meetings.• Experienced in model design from simple decision trees and Markov models through to complex simulation models including interactional effects.• Considerable experience in utility mapping, sequential modelling, the fitting of long-term survival curves to complex trial data, techniques for incorporating single-arm trial data and the use of non-RCT information to validate and inform long-term modelling.• Complex data analysis through spreadsheet and database manipulation. • Experienced in model and HTA submission review – firstly in assessing the strategy to ensure the optimum chance of success and secondly in identifying any logical or calculation errors.• Experienced QC and review – primary reviewer for models built internally by multiple large pharmaceutical companies.• Wide variety of therapeutic areas with specialism in oncology and mental health.Specialties: Health economics, modelling, simulation, data analysis, cost utility analysis, cost benefit analysis